Global Risk Indicator and Therapy for Older Patients With Diffuse Large B-Cell Lymphoma: A Population-Based Study

摘要

PURPOSE: To examine the impact of global risk, a measure comprising age, comorbidities, function, and cognitive statuses, on treatment selection and outcomes among older home care recipients with diffuse large B-cell lymphoma. METHODS: From SEER-Medicare, we selected home care recipients diagnosed with diffuse large B-cell lymphoma in 2011-2015, who had pretreatment Outcome and Assessment Information Set (OASIS) evaluations. We created a global risk indicator categorizing patients as low-, moderate-, or high-risk on the basis of OASIS assessments. We examined the association of global risk with receipt of therapy and among chemotherapy recipients, with mortality, emergency department visits, hospitalization, and intensive care unit admission within 30 days from first treatment in logistic models, reporting adjusted odds ratios (OR) with 95 CI. We compared overall survival across risk groups estimating adjusted hazard ratios. RESULTS: Of the 1,232 patients (median age, 80 years), 65 received chemotherapy. High-risk patients (v moderate-risk) were less likely to receive any chemotherapy (OR, 0.50; 95 CI, 0.39 to 0.64) and curative regimens (OR, 0.59; 95 CI, 0.40 to 0.86) if treated, although even in the moderate-risk group, only 61 received curative regimens. High-risk patients were more likely to experience acute mortality (OR, 2.24; 95 CI, 1.43 to 3.52), emergency department visits (OR, 1.35; 95 CI, 1.00 to 1.83), hospitalization (OR, 1.60; 95 CI, 1.19 to 2.17), or intensive care unit admission (OR, 1.52; 95 CI, 1.04 to 2.22) and had inferior overall survival (hazard ratio, 1.41; 95 CI, 1.11 to 1.78). CONCLUSION: Global risk on the basis of OASIS is easily available, suggesting a potential way to improve patient selection for curative treatment and institution of preventive measures.